TD Cowen initiated coverage of Centessa (CNTA) with a Buy rating and no price target The firm says the company’s ORX750 has a “best in class profile as a transformative therapy” in excessive daytime sleepiness. Key opinion leaders highlight the significant unmet need that should support multiple competitive entrants and given ORX750’s potency and safety, TD expects clinical differentiation and commercial success in narcolepsy and other hypersomnia indications, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CNTA:
- Centessa Pharmaceuticals Secures $200 Million Loan Deal
- Centessa CEO Saha sells 55,000 ordinary shares
- Centessa management to meet with Oppenheimer
- Centessa price target raised to $28 from $24 at Guggenheim
- Alkermes price target raised to $31 from $28 at BofA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
